Astellas Pharma Inc. ALPMF
Set alert
At close · Oct 30
- YTD
- +8.35%
- 1 year
- +28.91%
- Open
- 15.00
- Prev close
- 17.40
- Mkt cap
- 25.59B
- Vol
- 341
- Avg vol
- 5.69K
- EPS
- 1.32
- P/E
- 10.81
More statistics
- Low
- 15.00
- High
- 15.00
- Earnings
- Nov 4, 2026
News
1 month ago benzinga.com
Merck Advances European Regulatory Approval For Keytruda Combination In Bladder Cancer
European committee backs Merck's Keytruda + Padcev combo for bladder cancer after Phase 3 trial slashes risk of recurrence by 47%.
2 months ago seekingalpha.com
Impax International Sustainable Economy Fund Q2 2026 Contributors And Detractors
The portfolio outperformed the MSCI EAFE benchmark in the second quarter of 2026. Contributors include Infineon Technologies, Tokyo Electron and Recruit Holdings. Detractors include Murata…
3 months ago benzinga.com
Pfizer, Astellas Expand PADCEV-Keytruda Label With FDA Nod In Bladder Cancer
FDA approves Pfizer and Astellas' PADCEV plus Keytruda for muscle-invasive bladder cancer, backed by Phase 3 survival data.
6 months ago seekingalpha.com
Astellas Pharma Inc. (ALPMY) Q4 2026 Earnings Call Transcript
Astellas Pharma Inc. (ALPMY) Q4 2026 Earnings Call Transcript
6 months ago seekingalpha.com
Astellas Pharma Inc. (ALPMY) Discusses R&D Strategy and Focus Areas in Innovative Healthcare Transcript
Astellas Pharma Inc. (ALPMY) Discusses R&D Strategy and Focus Areas in Innovative Healthcare Transcript
8 months ago seekingalpha.com
Vir Biotechnology: Up On Prostate Data And Astellas Deal - I'm (Long-Term) Bullish
Vir Biotechnology, Inc. surges on positive Phase 1 data for VIR-5500 and a major global partnership with Astellas in prostate cancer. VIR-5500 demonstrated a favorable safety profile and 45% ORR at…
8 months ago benzinga.com
What's Going On With Kyntra Bio Stock Tuesday?
Kyntra Bio announces positive data for FG-3246 plus enzalutamide in metastatic castration-resistant prostate cancer.
8 months ago prnewswire.com
Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer
- Astellas and Vir Biotechnology to co-develop and co-commercialize VIR-5500 through a sharing of expenses and revenues - - Astellas to lead commercialization of VIR-5500 in the U.S. with Vir…
8 months ago reuters.com
India's Lupin clears patent hurdle with Astellas Pharma, keeps Mirabegron sales in US
Indian drugmaker Lupin said on Tuesday it has settled a patent infringement dispute with Japan's Astellas Pharma over the bladder disorder drug Mirabegron, allowing it to continue selling the product…
9 months ago seekingalpha.com
Astellas Pharma Inc. (ALPMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Astellas Pharma Inc. (ALPMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
10 months ago benzinga.com
Why Is Monte Rosa Stock Trading Higher Today?
Monte Rosa reports interim Phase 1/2 data showing durable responses and manageable safety for MRT-2359 plus Pfizer's Xtandi in advanced prostate cancer patients.
1 year ago benzinga.com
Why Is Taysha Gene Therapies Stock Falling Friday?
Taysha Gene Therapies shares fall after regaining full rights to Rett syndrome drug TSHA-102 and finalizing FDA alignment for pivotal trial.
1 year ago seekingalpha.com
Astellas Pharma Inc. (ALPMF) Q4 2024 Earnings Call Transcript
Astellas Pharma Inc. (OTCPK:ALPMF) Q4 2024 Earnings Conference Call April 25, 2025 4:00 AM ET Company Participants Hiromitsu Ikeda - Chief Communications and IR Officer Naoki Okamura - Representative…
1 year ago seekingalpha.com
Astellas Pharma: Raising New, As Yet Unanswered Questions In Stomach Cancer And Moving Their Pipeline Forward
Astellas Pharma Inc. has a diverse pipeline with significant growth in oncology, driven by new approvals for drugs like zolbetuximab. Despite recent stock declines, ALPMF's revenue and core profits…
1 year ago seekingalpha.com
Astellas Pharma Inc. (ALPMF) Q3 2024 Earnings Call Transcript
Astellas Pharma Inc. (OTCPK:ALPMF) Q3 2024 Earnings Conference Call February 4, 2025 2:00 AM ET Company Participants Hiromitsu Ikeda - Chief Communications and IR Officer Atsushi Kitamura - Chief…
2 years ago seekingalpha.com
Astellas Pharma Inc. (ALPMF) Q1 2024 Earnings Call Transcript
Astellas Pharma Inc. (OTCPK:ALPMF) Q1 2024 Earnings Conference Call August 1, 2024 3:00 AM ET Company Participants Hiromitsu Ikeda - Chief Communications and IRO Tadaaki Taniguchi - CMO Claus Zieler…
2 years ago seekingalpha.com
Astellas Pharma Inc. (ALPMF) Q4 2023 Earnings Call Transcript
Astellas Pharma Inc. (OTCPK:ALPMF) Q4 2023 Results Conference Call April 25, 2024 4:00 AM ET Company Participants Hiromitsu Ikeda - Chief Communications and Investor Relations Officer Naoki Okamura -…
2 years ago prnewswire.com
China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for enfortumab vedotin with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
- Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival vs platinum-containing chemotherapy- - If approved, enfortumab…
2 years ago seekingalpha.com
Astellas Pharma Inc. (ALPMF) Q3 2023 Earnings Call Transcript
Astellas Pharma Inc. (ALPMF) Q3 2023 Earnings Call Transcript
2 years ago prnewswire.com
EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Children
- Astellas contributed to the development of a pediatric formulation to treat schistosomiasis as a member of the Pediatric Praziquantel Consortium - TOKYO , Dec. 17, 2023 /PRNewswire/ -- Astellas…
3 years ago seekingalpha.com
Astellas Pharma Inc. (ALPMF) Q2 2023 Earnings Call Transcript
Astellas Pharma Inc. (OTCPK:ALPMF) Q2 2023 Earnings Conference Call November 1, 2023 3:00 AM ET Company Participants Hiromitsu Ikeda - Corporate Head, Advocacy & Relations Atsushi Kitamura - Chief…
3 years ago seekingalpha.com
Astellas Pharma Inc. (ALPMF) Q2 2023 Earnings Call Transcript
Astellas Pharma Inc. (OTCPK:ALPMF) Q2 2023 Earnings Conference Call August 1, 2023 4:00 AM ET Company Participants Hiromitsu Ikeda - Corporate Head, Advocacy and Relations Naoki Okamura -…
3 years ago prnewswire.com
Astellas Completes Acquisition of Iveric Bio
TOKYO and PARSIPPANY, N.J. , July 11, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that it has successfully completed the…
3 years ago marketwatch.com
You can't rely on indexes to pick international stocks, this 5-star fund manager says. Here are 3 of his top selections.
You have probably seen coverage of a renewed interest in Japanese stocks among well-known investors, including Berkshire Hathaway BRK.B, -0.57% CEO Warren Buffett. But Krishna Mohanraj, who runs a…
3 years ago proactiveinvestors.com
Iveric Bio stock surges on Astellas Pharma takeover deal
Iveric Bio Inc shares climbed 16% to $38.01 on Monday after the US drugmaker agreed to be acquired by Japan's Astellas Pharma for $40 per share in cash or total consideration of about $5.9 billion.…
-
6 years ago benzinga.com
Stocks That Hit 52-Week Highs On Tuesday
Stocks That Hit 52-Week Highs On Tuesday